BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals...
BC Extra | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

In a play to expand its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health in a deal valued at $2.8 billion. The deal also helps accelerate a...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BioCentury | May 3, 2019
Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
BC Week In Review | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
BC Extra | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
BC Week In Review | Sep 14, 2018
Financial News

Epic raises $52M series E

Epic Sciences Inc. (San Diego, Calif.) raised $52 million in a series E round led by Blue Ox Healthcare Partners. Fellow new investors Deerfield Management and Varian Medical Systems Inc. (NYSE:VAR) joined existing investors Altos...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
BC Week In Review | Jun 3, 2018
Clinical News

Oncotype DX identifies breast cancer patients who can be spared chemotherapy

An open-label, international Phase III trial conducted by NCI showed that the Oncotype DX breast cancer assay from Genomic Health Inc. (NASDAQ:GHDX) identified a subgroup of women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer...
Items per page:
1 - 10 of 217
BC Extra | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

Neuroimmunology and immuno-oncology company Alector Inc. (NASDAQ:ALEC) hired Shehnaaz Suliman as president and COO and made Richard Scheller and Thomas Südhof co-chairs of its strategic portfolio advice and review committee. Suliman was SVP of corporate...
BioCentury | Nov 23, 2019
Product Development

New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals...
BC Extra | Jul 30, 2019
Company News

How $2.8B Genomic Health deal catapults Exact beyond Cologuard

In a play to expand its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health in a deal valued at $2.8 billion. The deal also helps accelerate a...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BioCentury | May 3, 2019
Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
BC Week In Review | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
BC Extra | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
BC Week In Review | Sep 14, 2018
Financial News

Epic raises $52M series E

Epic Sciences Inc. (San Diego, Calif.) raised $52 million in a series E round led by Blue Ox Healthcare Partners. Fellow new investors Deerfield Management and Varian Medical Systems Inc. (NYSE:VAR) joined existing investors Altos...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
BC Week In Review | Jun 3, 2018
Clinical News

Oncotype DX identifies breast cancer patients who can be spared chemotherapy

An open-label, international Phase III trial conducted by NCI showed that the Oncotype DX breast cancer assay from Genomic Health Inc. (NASDAQ:GHDX) identified a subgroup of women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer...
Items per page:
1 - 10 of 217